Abortion pills — a combo of two drugs, mifepristone and misoprostol — are on notice: on April 7, 2023, a federal judge said the FDA’s approval of mifepristone was invalid. And then, not more than an hour later, another federal judge in a separate case said that mifepristone had to stay on the market in certain states. With these two contradictory rulings, mifepristone — and medical abortion, in general — is in the crosshairs. So, today, we want to rewind to an episode we made last year. It looks at these two drugs over the last 40 years, from their origin stories and development, to how their administration from doctors to patients keeps evolving. This story, for us, started…
Special thanks to Mariana Prandini Assis and Pam Belluck.
Reported by - Molly Webster, Avir Mitra Produced by Sarah Qariwith mixing help from - Arianne WackFact-checking by - Diane Kellyand Edited by - Becca BresslerCITATIONS:
From one of our sources, Abigail Aiken: “Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: A population based study” (https://zpr.io/kG3hNFXM4kb9)
Our newsletter comes out every Wednesday. It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)!
Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today.
Leadership support for Radiolab’s science programming is provided by the Gordon and Betty Moore Foundation, Science Sandbox, a Simons Foundation Initiative, and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.